New hope for Parkinson's patients struggling with drooling
NCT ID NCT06319118
Summary
This completed study tested whether dihydroergotine mesylate extended-release tablets could safely reduce drooling in people with Parkinson's disease who also have some cognitive impairment. Researchers compared the medication against a placebo in 120 participants over 12 weeks. The study also looked at whether the treatment might affect patients' thinking abilities.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVATION IN PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Arilliated Hospital of Soochow University
Suzhou, Jiangsu, 215004, China
Conditions
Explore the condition pages connected to this study.